Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute promyelocytic leukaemia.

J M Goldman

    British Medical Journal
    |March 2, 1974
    PubMed
    Summary

    Acute promyelocytic leukaemia (A.P.L.) is a rare acute myeloid leukaemia presenting with severe bleeding. Early recognition and specialized treatment are crucial for achieving long-term remission in A.P.L. patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia.

    Blood·1996
    Same author

    Overexpression of EVI-1 in blast crisis of chronic myeloid leukemia.

    Leukemia·1996
    Same author

    Organ-specific contribution to circulating C7 levels by the bone marrow and liver in humans.

    European journal of immunology·1996
    Same author

    Phenotype and progeny of primitive adherent human hematopoietic progenitors.

    Leukemia·1996
    Same author

    Expression of the LH2 gene in chronic myeloid leukaemia cells.

    Leukemia·1996
    Same author

    Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results.

    Leukemia·1996

    Area of Science:

    • Hematology
    • Oncology
    • Internal Medicine

    Background:

    • Acute promyelocytic leukaemia (A.P.L.) is a distinct subtype of acute myeloid leukaemia.
    • A.P.L. is characterized by severe bleeding, thrombocytopenia, and coagulopathy.
    • Key laboratory findings include low fibrinogen and elevated fibrin degradation products, indicative of disseminated intravascular coagulation and secondary fibrinolysis.

    Purpose of the Study:

    • To highlight the critical importance of early recognition of A.P.L.
    • To emphasize the necessity of prompt and appropriate treatment for A.P.L. patients.
    • To underscore the benefits of specialized center management for improving patient outcomes.

    Main Methods:

    • This abstract discusses the clinical and laboratory features of A.P.L.
    • It reviews the pathophysiology involving disseminated intravascular coagulation and secondary fibrinolysis.
    • The text emphasizes diagnostic criteria and treatment considerations.

    Main Results:

    • Optimal management can lead to complete remission in up to 50% of patients for two years or more.
    • Delayed diagnosis and suboptimal treatment contribute to mortality.
    • Increased awareness of A.P.L. can significantly improve survival rates.

    Conclusions:

    • A.P.L. requires prompt diagnosis and urgent, specialized treatment.
    • Familiarity with A.P.L.'s unique presentation is essential for clinicians.
    • Effective management in specialized centers offers the best prognosis for patients with this rare leukaemia.

    Related Experiment Videos